Advertisement

Autoimmune disorders and venous thromboembolism: An update from the COMMAND VTE registry

Published:October 24, 2020DOI:https://doi.org/10.1016/j.ejim.2020.10.017
      There are various well-known predisposing risk factors for development of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), and several studies reported that autoimmune disorder is one of important risk factors for development of VTE [
      • Zoller B.
      • Li X.
      • Sundquist J.
      • Sundquist K
      Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.
      ,
      • Matta F.
      • Singala R.
      • Yaekoub A.Y.
      • Najjar R.
      • Stein P.D
      Risk of venous thromboembolism with rheumatoid arthritis.
      ]. Furthermore, autoimmune disorder is thought to be a relatively strong risk factor for VTE recurrence, and extended anticoagulation therapy are recommended for prevention of VTE recurrence in patients with autoimmune disorders[
      • Konstantinides S.V.
      • Meyer G.
      The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
      ]. However, it remains controversial whether patients with autoimmune disorders have higher risk for clinical events after VTE than those without[
      • Sada P.R.
      • Lopez-Nunez J.J.
      • Samperiz A.
      • et al.
      Venous thromboembolism in patients with autoimmune disorders: findings from the RIETE registry.
      ]. Therefore, we sought to evaluate the clinical characteristics, management strategies, and long-term outcomes of patients with autoimmune disorders after excluding patients with active cancer in a large observational database in Japan.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Zoller B.
        • Li X.
        • Sundquist J.
        • Sundquist K
        Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden.
        Lancet. 2012; 379: 244-249
        • Matta F.
        • Singala R.
        • Yaekoub A.Y.
        • Najjar R.
        • Stein P.D
        Risk of venous thromboembolism with rheumatoid arthritis.
        Thromb Haemost. 2009; 101: 134-138
        • Konstantinides S.V.
        • Meyer G.
        The 2019 ESC guidelines on the diagnosis and management of acute pulmonary embolism.
        Eur Heart J. 2019; 40: 3453-3455
        • Sada P.R.
        • Lopez-Nunez J.J.
        • Samperiz A.
        • et al.
        Venous thromboembolism in patients with autoimmune disorders: findings from the RIETE registry.
        Angiology. 2020; 71: 131-138
        • Yamashita Y.
        • Morimoto T.
        • Amano H.
        • et al.
        Anticoagulation therapy for venous thromboembolism in the real world- from the COMMAND VTE registry.
        Circ J. 2018; 82: 1262-1270
        • Yamashita Y.
        • Morimoto T.
        • Amano H.
        • et al.
        Usefulness of simplified pulmonary embolism severity index score for identification of patients with low-risk pulmonary embolism and active cancer: from the COMMAND VTE registry.
        Chest. 2020; 157: 636-644
        • Schulman S.
        • Kearon C.
        Subcommittee on control of anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.
        J Thromb Haemost. 2005; 3: 692-694
        • Group JCSJW.
        Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2009).
        Circ J. 2011; 75: 1258-1281
        • Jaff M.R.
        • McMurtry M.S.
        • Archer S.L.
        • et al.
        Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association.
        Circulation. 2011; 123: 1788-1830
        • Kearon C.
        • Akl E.A.
        • Ornelas J.
        • et al.
        Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.
        Chest. 2016; 149: 315-352